AGIO Agios Pharmaceuticals, Inc.
$38.03▲ +3.20%
Healthcare
Other
After hours
$38.03▲ +0.00%
Oct 27, 4:00 PM ET
Volume 739.0K
Avg Volume (10D) 1.21M
Key Metrics & Fundamentals
Market Cap
$2.27B
P/E Ratio
–
Div Yield
0.00%
52W Range
22.24 - 46.00
% vs 50 MA
13.29%
% vs 200 MA
20.38%
RSI-14
69.3
MACD Histogram
+0.6800
Beta (1Y vs SPY)
0.46
Free Cash Flow
-$83.52M
Gross Rev
$44.75M
Gross Profit
$41.75M
EBITDA
-$109.20M
COGS
$3.00M
Operating Exp
$152.30M
Operating Income
-$110.55M
EBIT
-$110.55M
Pretax Income
-$100.70M
Net Income
-$100.70M
EPS (Diluted)
-1.69
Price & Volume History
Loading chart…
Recent News
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Zacks · Oct 21, 2026 9:45 AM ET
Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?
Simply Wall St. · Oct 20, 2026 7:23 PM ET
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
CNW Group · Oct 20, 2026 8:59 AM ET
FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings
Stocktwits · Oct 19, 2026 5:43 AM ET
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
Zacks · Oct 16, 2026 8:41 AM ET
4 High-Risk Stocks Built for Big Returns
Motley Fool · Oct 14, 2026 6:28 AM ET
Agios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call Date
Simply Wall St. · Oct 9, 2026 10:12 PM ET
Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current Sales
Simply Wall St. · Oct 9, 2026 6:08 PM ET
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
GlobeNewswire · Oct 8, 2026 7:00 AM ET
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
Zacks · Oct 6, 2026 9:55 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AGIO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.